Ozlen Balcioglu

Ozlen Balcioglu

Auto-generated profile, based on publicly available information

Ozlen Balcioglu

Division of Oncology, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Way, Salt Lake City, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
CGChinmayee Goda
Chinmayee Goda
RKRohan Kulkarni
Rohan Kulkarni
YBYaphet Bustos
Yaphet Bustos
WLWenjun Li
Wenjun Li
ARAlexander Rudich
Alexander Rudich
ADAdrienne M. Dorrance
Adrienne M. Dorrance
Leukemias arise from recurrent clonal mutations in hematopoietic stem/progenitor cells (HSPCs) that cause profound changes in the bone marrow microenvironment (BMM) favoring leukemic stem cell (LSC) growth over normal HSPCs. Understanding the cross talk between preleukemic mutated HSPCs and the BMM is critical to develop novel therapeutic strategies to prevent leukemogenesis. We hypothesize that preleukemic-LSCs (pLSCs) induce BMM changes critical for leukemogenesis. Using our AML-murine model, we performed single-cell RNA-sequencing of preleukemic BMM (pBMM) cells. We found normal HSC (nHSC)-regulating LepR+ mesenchymal stem cells, and endothelial cells were decreased, along with increases in CD55+ fibroblasts and pericytes. Preleukemic CD55+ fibroblasts had higher proliferation rates and decreased collagen expression, suggesting extracellular matrix remodeling during leukemogenesis. Importantly, co-culture assays found preleukemic CD55+ fibroblasts expanded pLSCs significantly over nHSCs. In conclusion, we have identified a distinct pBMM and a novel CD55+ fibroblast population that is expanded in pBMM that promote fitness of pLSCs over nHSCs.

14 September 2024 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
OBOzlen Balcioglu
Ozlen Balcioglu
BGBrooke L. Gates
Brooke L. Gates
DFDavid W. Freeman
David W. Freeman
BHBerhane M. Hagos
Berhane M. Hagos
EMElnaz Mirzaei Mehrabad
Elnaz Mirzaei Mehrabad
BSBen Spike
Ben Spike
Cell state control is crucial for normal tissue development and cancer cell mimicry of stem/progenitor states, contributing to tumor heterogeneity, therapy resistance, and progression. Here, we demonstrate that the cell surface glycoprotein Mcam maintains the tumorigenic luminal progenitor (LP)-like epithelial cell state, leading to Basal-like mammary cancers. In the Py230 mouse mammary carcinoma model, Mcam knockdown (KD) destabilized the LP state by deregulating the Ck2/Stat3 axis, causing a switch to alveolar and basal states, loss of an estrogen-sensing subpopulation, and resistance to tamoxifen—an effect reversed by Ck2 and Stat3 inhibitors. In vivo, Mcam KD blocked generation of Basal-like tumors and Sox10+Krt14+ cells. In human tumors, MCAM loss was largely exclusive of the Basal-like subtype, linked instead to proliferative Luminal subtypes, including often endocrine-resistant Luminal B cancers. This study has implications for developing therapies targeting MCAM, CK2, and STAT3 and their likely effective contexts.

12 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
OBOzlen Balcioglu
Ozlen Balcioglu
BGBrooke L. Gates
Brooke L. Gates
DFDavid W. Freeman
David W. Freeman
BHBerhane M. Hagos
Berhane M. Hagos
EMElnaz Mirzaei Mehrabad
Elnaz Mirzaei Mehrabad
BSBen Spike
Ben Spike
Breast cancers are categorized into subtypes with distinctive therapeutic vulnerabilities and prognoses based on their expression of clinically targetable receptors and gene expression patterns mimicking different cell types of the normal gland. Here, we tested the role of Mcam in breast cancer cell state control and tumorigenicity in a luminal progenitor-like murine tumor cell line (Py230) that exhibits lineage and tumor subtype plasticity. Mcam knockdown Py230 cells show augmented Stat3 and Pi3K/Akt activation associated with a lineage state switch away from a hormone-sensing/luminal progenitor state toward alveolar and basal cell related phenotypes that were refractory to growth inhibition by the anti-estrogen therapeutic, tamoxifen. Inhibition of Stat3, or the upstream activator Ck2, reversed these cell state changes. Mcam binds Ck2 and acts as a regulator of Ck2 substrate utilization across multiple mammary tumor cell lines. In Py230 cells this activity manifests as increased mesenchymal morphology, migration, and Src/Fak/Mapk/Paxillin adhesion complex signaling in vitro , in contrast to Mcam’s reported roles in promoting mesenchymal phenotypes. In vivo , Mcam knockdown reduced tumor growth and take rate and inhibited cell state transition to Sox10+/neural crest like cells previously been associated with tumor aggressiveness. This contrasts with human luminal breast cancers where MCAM copy number loss is highly coupled to Cyclin D amplification, increased proliferation, and the more aggressive Luminal B subtype. Together these data indicate a critical role for Mcam and its regulation of Ck2 in control of breast cancer cell state plasticity with implications for progression, evasion of targeted therapies and combination therapy design. HIGHLIGHTS: Mcam is expressed by diverse breast cancer subtypes. Mcam regulates breast cancer cell state plasticity. Mcam maintains the mammary luminal progenitor state. Mcam attenuates Stat activity. Mcam dictates Ck2 substrate utilization.